Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.

Transaction summary

Transaction and post-transaction values based connected SEC Form 4 reported terms ($19.69).

Key questions

• How does this acquisition interaction Paul A. LaViolette's ownership successful Pulse Biosciences?
  This transaction accrued his nonstop ownership from 846 to 15,846 shares, representing a ~1,773.05% summation successful nonstop holdings and bringing his post-transaction involvement to astir 0.02% of outstanding shares arsenic of the latest filing.

• Was this acquisition conducted done immoderate derivative oregon indirect means?
  No; each 15,000 shares were acquired done nonstop open-market purchases, with nary engagement of options, warrants, oregon indirect entities specified arsenic trusts oregon household offices.

• How does the transaction terms comparison to the prevailing marketplace levels?
  The shares were acquired astatine astir $19.69 per share, adjacent to the May 11, 2026 marketplace adjacent of $19.08, with the existent banal terms astatine $24.55 arsenic of May 15, 2026, reflecting a ~24.7% summation from the acquisition terms implicit 4 days.

• What does this acquisition awesome regarding management's posture toward stock accumulation?
  This is the CEO’s archetypal open-market acquisition successful the disposable filing history, materially expanding his nonstop involvement and signaling a committedness to idiosyncratic superior astatine hazard aft a play with constricted ownership changes.

Company overview

* 1-year terms alteration calculated utilizing May 11th, 2026 arsenic the notation date.

Company snapshot

• Pulse Biosciences develops and commercializes the CellFX System, a software-enabled level utilizing Nano-Pulse Stimulation exertion to present targeted bioelectric treatments for aesculapian conditions.

• The institution offers the CellFX System utilizing its proprietary Nano-Pulse Stimulation exertion for usage by healthcare providers.

• The CellFX System is utilized to present non-thermal attraction options for cellular-based aesculapian conditions.

Pulse Biosciences is simply a healthcare exertion institution specializing successful precocious bioelectric medicine. Its strategy centers connected commercializing the CellFX System, which offers a caller attack to treating targeted cells portion preserving steadfast tissue.